Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NMT Medical gets CE-mark for BioSTAR heart implant

This article was originally published in Clinica

Executive Summary

NMT Medical has CE-marked for sale in Europe its BioSTAR device - a bioabsorbable septal repair implant technology and Rapid Transport delivery system. The firm, which has also received Canadian approval for the product, plans to launch BioSTAR in Europe and Canada early in the third quarter of 2007. The BEST (BioSTAR Evaluation Study) clinical trial of the device found that it had closure rates of 92% at 30 days, and 96% at six months, respectively, claimed the Boston, Massachusetts firm.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049064

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel